Literature DB >> 14634805

Inhibition of HIV-1 infection by monoclonal antibodies to carbohydrates of Schistosoma mansoni.

Marco Antônio Gomes Mello1, Rita Elizabeth Mascarenhas, Geraldo Argolo Ferraro, Donald Harn, Marco Galvão-Castro, Dumith Chequer Bou-Habib.   

Abstract

Patients infected with HIV-1 develop a potent humoral immune response against the virus, but HIV-1 primary isolates are remarkably resistant to neutralizing antibodies. Considering that the envelope glycoprotein of HIV-1 (gp120/41) is heavily glycosylated, we investigated whether anti-carbohydrate antibodies could inhibit HIV-1 infection in vitro. We studied the neutralizing activity of three monoclonal antibodies (mAbs) raised to carbohydrates of Schistosoma mansoni, against seven primary isolates of HIV-1. Assays were performed infecting peripheral blood mononuclear cells from normal donors with viral isolates previously treated with mAbs. Viral strains used were tropic for the coreceptors CCR5, CXCR4, and dual-tropic ones. We found that the anti-glycan mAbs vigorously inhibited HIV-1 infection, regardless of the preferential coreceptor usage of the isolate, in a dose-response manner. Importantly, five isolates were resistant to neutralization by two HIV-1 antibody-positive human sera endowed with potent anti-HIV-1 inhibitory activity. Our findings suggest that carbohydrates of the HIV-1 viral envelope may be a target of an effective humoral immune response elicited by vaccination.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 14634805     DOI: 10.1007/s00430-003-0214-x

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  31 in total

1.  HIV-1 diversity in Brazil: genetic, biologic, and immunologic characterization of HIV-1 strains in three potential HIV vaccine evaluation sites. Brazilian Network for HIV Isolation and Characterization.

Authors:  V Bongertz; D C Bou-Habib; L F Brígido; M Caseiro; P J Chequer; J C Couto-Fernandez; P C Ferreira; B Galvão-Castro; D Greco; M L Guimarães; M I Linhares de Carvalho; M G Morgado; C A Oliveira; S Osmanov; C A Ramos; M Rossini; E Sabino; A Tanuri; M Ueda
Journal:  J Acquir Immune Defic Syndr       Date:  2000-02-01       Impact factor: 3.731

2.  Decrease in human immunodeficiency virus type 1 load during acute dengue fever.

Authors:  George Watt; Pacharee Kantipong; Krisada Jongsakul
Journal:  Clin Infect Dis       Date:  2003-04-04       Impact factor: 9.079

3.  Suppression of CCR5- but not CXCR4-tropic HIV-1 in lymphoid tissue by human herpesvirus 6.

Authors:  J C Grivel; Y Ito; G Fagà; F Santoro; F Shaheen; M S Malnati; W Fitzgerald; P Lusso; L Margolis
Journal:  Nat Med       Date:  2001-11       Impact factor: 53.440

4.  Jitters jeopardize AIDS vaccine trials.

Authors:  J Cohen
Journal:  Science       Date:  1993-11-12       Impact factor: 47.728

5.  Suppression of human immunodeficiency virus replication during acute measles.

Authors:  William J Moss; Judith J Ryon; Mwaka Monze; Felicity Cutts; Thomas C Quinn; Diane E Griffin
Journal:  J Infect Dis       Date:  2002-03-25       Impact factor: 5.226

6.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

7.  The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Authors:  Christopher N Scanlan; Ralph Pantophlet; Mark R Wormald; Erica Ollmann Saphire; Robyn Stanfield; Ian A Wilson; Hermann Katinger; Raymond A Dwek; Pauline M Rudd; Dennis R Burton
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

8.  Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization.

Authors:  D C Bou-Habib; G Roderiquez; T Oravecz; P W Berman; P Lusso; M A Norcross
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

9.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.

Authors:  P Borrow; H Lewicki; B H Hahn; G M Shaw; M B Oldstone
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

10.  A Schistosoma mansoni epitope recognized by a protective monoclonal antibody is identical to the stage-specific embryonic antigen 1.

Authors:  A I Ko; U C Dräger; D A Harn
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.